Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
08:30am, Friday, 01'st Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
07:25am, Tuesday, 15'th Oct 2024
Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 11'th Oct 2024
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
08:30am, Wednesday, 09'th Oct 2024
SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
08:30am, Monday, 23'rd Sep 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and comm
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
01:00pm, Friday, 06'th Sep 2024
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
07:05pm, Tuesday, 13'th Aug 2024
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
06:30pm, Tuesday, 13'th Aug 2024
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.
3 Stocks Under $15 That Could Make You a Millionaire
06:20am, Friday, 26'th Jul 2024
Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors.
Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript
06:41pm, Tuesday, 11'th Jun 2024
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chie
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
04:20pm, Tuesday, 11'th Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
08:30am, Friday, 07'th Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi
Vistagen to Present at the Jefferies Global Healthcare Conference
08:30am, Wednesday, 29'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
08:30am, Thursday, 23'rd May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affec
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
06:59am, Tuesday, 14'th May 2024
Penny stocks can be super volatile, but the potential of a modest investment ballooning into a multi-bagger is tough to pass up. These stocks represent the riskier end of the public equity range.
